|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
BEFREE |
Therefore in this study, we examined the genetic roles of FABP5 and 3 in schizophrenia (N = 1,900 in combination with controls) and FABP7, 5, and 3 in bipolar disorder (N = 1,762 in the case-control set).
|
19554614 |
2010 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
In postmortem brains, we detected altered mRNA expression levels of FABP5 in schizophrenia, and of FABP7 in ASD and altered FABP5 in peripheral lymphocytes.
|
25027319 |
2014 |
|
Schizophrenia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In postmortem brains, we detected altered mRNA expression levels of FABP5 in schizophrenia, and of FABP7 in ASD and altered FABP5 in peripheral lymphocytes.
|
25027319 |
2014 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Therefore in this study, we examined the genetic roles of FABP5 and 3 in schizophrenia (N = 1,900 in combination with controls) and FABP7, 5, and 3 in bipolar disorder (N = 1,762 in the case-control set).
|
19554614 |
2010 |
|
Liver carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Cell proliferation, invasion, and migration in vitro were enhanced by upregulation of FABP5 and decreased by downregulation of FABP5 in HCC cell lines.
|
28374947 |
2017 |
|
Liver carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
FABP5 mRNA expression was also associated with adverse HCC characteristics.
|
29957468 |
2018 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.
|
21472284 |
2012 |
|
Myocardial Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Fatty acid-binding protein 4 was positively associated with age, body mass index (BMI), FABP5, very-low-density lipoprotein cholesterol (VLDLc), non-high-density lipoprote in cholesterol (non-HDLc), Apolipoprotein B 100 (ApoB100), triglycerides, glycerol, glucose, and hsCRP (<i>p</i> < .05), and was negatively associated with HDLc (<i>p</i> < .005) in breast cancer patients.
|
28701570 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
The expression and subcellular distribution of two RA-binding proteins, FABP5 and CRABP2, has already been shown to play critical roles in breast cancer cell response to RA.
|
26142905 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Further, immunohistochemistry was performed to detect differential expression of ATGL and FABP5 in breast cancer tissue sections.
|
29914512 |
2018 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
FABP5 knockdown in breast cancer cell lines demonstrates a correlation between FABP5 levels and growth response to RA.
|
21356353 |
2011 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our studies show that FABP5 has a role in both host and tumor cell during breast cancer progression.
|
25779666 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In this study, the inhibitory effects of ATPR on the proliferation, invasion, and migration of breast cancer (BC) cells, and the relationship between ATPR and the expression of the intracellular lipid-binding proteins CRABP2 and FABP5 were investigated.
|
29731607 |
2018 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
In this study, we show that FABP5 is highly upregulated in human breast cancers and we provide genetic evidence of the pathophysiologic significance of FABP5 in mammary tumorigenesis.
|
23722546 |
2013 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
To further functionally characterise the FABP5-PPARγ-VEGF signal transduction pathway, we have, in this work, investigated the molecular mechanisms involved in its tumorigenicity promoting role in prostate cancer.
|
26814431 |
2016 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
FABP5 was overexpressed in PCa compared to BPH in the cohorts analyzed by qRT-PCR (radical prostatectomy p = 0.003, p = 0.010; pTUR-P p = 0.002).
|
30701334 |
2020 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our findings position FABP5 as a key driver of lipid-mediated metastasis and suggest that disruption of lipid signaling via FABP5 inhibition may constitute a new avenue to treat metastatic PCa.
|
31831821 |
2019 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Fatty acid-binding protein 5 (FABP5) is an intracellular lipid carrier whose expression is upregulated in metastatic PCa and increases cell growth, invasion, and tumor formation.
|
31661167 |
2020 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
In contrast to numerous studies conducted to investigate the crucial role of fatty acid binding protein 5 (FABP5) in prostate cancer, investigations on the possible involvement of other FABPs are rare.
|
27779102 |
2016 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
FABP5 in urinary EVs could be a potential biomarker of high GS PCa.
|
28211531 |
2017 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our findings position FABP5 as a key driver of lipid-mediated metastasis and suggest that disruption of lipid signaling via FABP5 inhibition may constitute a new avenue to treat metastatic PCa.
|
31831821 |
2019 |
|
Prostate carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Fatty acid-binding protein 5 (FABP5) is an intracellular lipid carrier whose expression is upregulated in metastatic PCa and increases cell growth, invasion, and tumor formation.
|
31661167 |
2020 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
To further functionally characterise the FABP5-PPARγ-VEGF signal transduction pathway, we have, in this work, investigated the molecular mechanisms involved in its tumorigenicity promoting role in prostate cancer.
|
26814431 |
2016 |
|
Prostate carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In contrast to numerous studies conducted to investigate the crucial role of fatty acid binding protein 5 (FABP5) in prostate cancer, investigations on the possible involvement of other FABPs are rare.
|
27779102 |
2016 |